T2 Biosystems (TTOO) 8-K Condensed Consolidated Statements of Operations and Comprehensive Loss

Exhibit 99.1

T2 Biosystems, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(Unaudited)

	Three Months Ended December 31,						Twelve Months Ended December 31,
	2016			2015			2016			2015
Revenue:
Product revenue	$	579		$	343		$	1,747		$	599
Research revenue	331			668			2,333			2,214
Total revenue	910			1,011			4,080			2,813
Costs and expenses:
Cost of product revenue	2,171			910			6,872			1,740
Research and development expenses	5,851			6,638			24,009			25,362
Selling, general and administrative expenses	5,795			5,008			24,077			19,094
Total costs and expenses	13,817			12,556			54,958			46,196
Loss from operations	(12,907		)	(11,545		)	(50,878		)	(43,383		)
Interest expense, net	(1,682		)	(513		)	(4,098		)	(1,967		)
Other income, net	40			26			172			60
Net loss and comprehensive loss	$	(14,549	)	$	(12,032	)	$	(54,804	)	$	(45,290	)
Net loss per share - basic and diluted	$	(0.48	)	$	(0.56	)	$	(2.11	)	$	(2.21	)
Weighted-average number of common shares used in computing net loss per share	30,457,063			21,322,799			26,015,751			20,501,748

T2 Biosystems, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)

	December 31, 2016			December 31, 2015
Assets
Current Assets:
Cash and cash equivalents	$	73,488		$	73,662
Accounts receivable	327			369
Prepaid expenses and other current assets	820			838
Inventory, net	803			683
Total current assets	75,438			75,552
Property and equipment, net	13,589			10,655
Restricted cash	260			260
Other assets	281			358
Total assets	$	89,568		$	86,825
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	962		$	1,228
Accrued expenses and other current liabilities	4,908			4,162
Current portion of notes payable	1,269			4,449
Current portion of lease incentives	301			268
Deferred revenue	2,445			2,146
Total current liabilities	9,885			12,253
Notes payable, net of current portion	39,504			26,121
Lease incentives, net of current portion	792			1,076
Other liabilities	49			436
Commitments and contingencies	—			—
Stockholders’ equity:
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2016 and December 31, 2015; 30,482,712 and 24,175,381 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively	30			24
Additional paid-in capital	242,997			195,800
Accumulated deficit	(203,689		)	(148,885		)
Total stockholders’ equity	39,338			46,939
Total liabilities and stockholders’ equity	$	89,568		$	86,825